Recent studies have shown that the overexpression of USP7 in prostate cancer correlates with tumor aggressiveness and that the inhibition of USP7 can induce the apoptosis of multiple myeloma (MM) cells resistant to conventional and bortezomib therapies [5, 6]. Here, USP7 is linked to Miyoshi myopathy.